Ewing's Sarcoma Treatment Market to grow by USD 205.09 million from 2024-2028; North America to account for 48% of market growth - Technavio

NEW YORK, Nov. 20, 2023 /PRNewswire/ -- The

Ewing's sarcoma treatment market size is expected to grow by

USD 205.09 million from 2023 to 2028. In addition, the momentum of the market will progress at a

CAGR of 6.26% during the forecast period, according to Technavio Research. The market is categorized by End-user (Hospitals, Specialty clinics, and Others), Type (Combination therapy and Monotherapy), and Geography (North America, Europe, Asia, and Rest of World (ROW)). Geo EXPLAINATION.

This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Read a Free PDF Sample Report

Continue Reading

Preview

来源: PRNewswire

Technavio has announced its latest market research report titled Global Ewing's Sarcoma Treatment Market 2024-2028

Company Profile:

Actiza Pharmaceutical Pvt. Ltd., Advantech Co. Ltd., Amneal Pharmaceuticals Inc., Baxter International Inc., Bristol Myers Squibb Co., Cellectar Biosciences Inc., Daiichi Sankyo Co. Ltd., Eli Lilly and Co., Fresenius Kabi AG, GlaxoSmithKline Plc, Gradalis Inc., Johnson and Johnson, LGM Pharma LLC, Merck and Co. Inc., Novartis AG, Ocean pharmaceutical, Pfizer Inc., PharmaMar SA, Salvavidas, UPMC Hillman Cancer Center

Advantech Co. Ltd.: The company offers Ewings sarcoma treatment drugs such as INBRX-109 which is a tetravalent, agonistic antibody targeting death receptor 5 (DR5), a proapoptotic receptor for the trimeric tumor necrosis factor-related apoptosis-inducing ligand.

•    To gain access to more vendor profiles available with Technavio, buy the report!

Ewing's Sarcoma Treatment Market: Segmentation Analysis

The

hospitals segment will be significant during the forecast period. Hospitals procure medical products and consumables in bulk and engage closely with many suppliers, reimbursement authorities, and government organizations.

Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a PDF Sample Report

"Besides analyzing the current market scenario, our report examines historic data from 2017 to 2021"- Technavio

Ewing's Sarcoma Treatment Market: Driver & Trend:

Driver

Growing awareness about and funding for Ewings sarcoma

Regulatory incentives for Ewings sarcoma treatment

Financial assistance programs and reimbursement schemes

The regulatory incentives for Ewings sarcoma treatment drive market growth. Ewings sarcoma is a rare bone tumor that occurs in childhood and no cure has been developed for it. This is because rare diseases lack sponsors owing to the expensive research and the prospect of limited profit. According to the NH, approximately 3 per 1 million children each year are diagnosed with Ewing's sarcoma. It accounts for about 1.5 percent of all childhood cancers, and it is the second-most common type of bone tumor in children.

Strategic alliances among market vendors are a key trend in the Ewing's sarcoma treatment market. Identify key trends, drivers, and challenges in the market. Download a sample report to gain access to this information.

Related Reports:

The

fallopian tube cancer therapeutics market size is estimated to grow by USD 832.01 million at a CAGR of 10.35% between 2023 and 2028.

The

sarcoma therapeutics market size is expected to increase by USD 1.18 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 9%.

What are the key data covered in this Ewing's sarcoma treatment market report?

CAGR of the market during the forecast period

Detailed information on factors that will drive the growth of the Ewing's sarcoma treatment market between 2023 and 2028.

Precise estimation of the Ewing's sarcoma treatment market size and its contribution to the market in focus on the parent market

Accurate predictions about upcoming trends and changes in consumer behavior

Growth of the Ewing's sarcoma treatment market across North America, Europe, Asia, and ROW

A thorough analysis of the market's competitive landscape and detailed information about vendors

Comprehensive analysis of factors that will challenge the growth of Ewing's sarcoma treatment market vendors.

ToC:

Executive Summary

Market Landscape

Market Sizing

Historic Market Sizes

Five Forces Analysis

Market Segmentation by End-user

Market Segmentation by Type

Market Segmentation by Geography

Customer Landscape

Geographic Landscape

Drivers, Challenges, & Trends

Company Landscape

Company Analysis

Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: [email protected]

Website: www.technavio.com

SOURCE Technavio

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。